A Phase 4, single-arm, open-label study designed to evaluate nirogacestat in premenopausal adult women with desmoid tumors or aggressive fibromatosis.
Principal Investigator
Dott. Giovanni Grignani
Contact Information for Access
Phase
FASE IV
Status
ATTIVO
Objective of the study
Tolerability, Toxicity, and Ovarian Function in Premenopausal Patients with Desmoid Tumors.
Desmoid
ClinicalTrials.gov ID NCT07176689
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Pathologies
Sarcomi tumori rari e GIST
Medication
Nirogacestat
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Premenopausal patients with desmoid tumors.
View the full study Back to search page